J. B. Chemicals & Pharmaceuticals (JBCHEPHARM) Stock Overview
Manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
JBCHEPHARM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
J. B. Chemicals & Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,809.90 |
| 52 Week High | ₹1,952.00 |
| 52 Week Low | ₹1,385.75 |
| Beta | -0.081 |
| 1 Month Change | -0.19% |
| 3 Month Change | 6.12% |
| 1 Year Change | -0.26% |
| 3 Year Change | 78.82% |
| 5 Year Change | 234.41% |
| Change since IPO | 2,296.43% |
Recent News & Updates
J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Nov 14
What J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) P/E Is Not Telling You
Oct 07J. B. Chemicals & Pharmaceuticals Limited Just Missed EPS By 8.9%: Here's What Analysts Think Will Happen Next
Aug 03Recent updates
J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Nov 14What J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) P/E Is Not Telling You
Oct 07J. B. Chemicals & Pharmaceuticals Limited Just Missed EPS By 8.9%: Here's What Analysts Think Will Happen Next
Aug 03Here's Why Shareholders Will Not Be Complaining About J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Pay Packet
Jul 31Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) A Risky Investment?
Jun 23J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
May 17J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 07J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Share Price Could Signal Some Risk
Jan 29We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 27J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 09J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price
Sep 24Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation
Aug 15J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well
Jun 28J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Apr 19J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Dec 22We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25
Aug 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50
Feb 11Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03Shareholder Returns
| JBCHEPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.6% | -1.3% | -1.7% |
| 1Y | -0.3% | -3.8% | -3.3% |
Return vs Industry: JBCHEPHARM exceeded the Indian Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: JBCHEPHARM exceeded the Indian Market which returned -3.5% over the past year.
Price Volatility
| JBCHEPHARM volatility | |
|---|---|
| JBCHEPHARM Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.0% |
Stable Share Price: JBCHEPHARM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: JBCHEPHARM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5,304 | Nikhil Chopra | www.jbpharma.com |
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms.
J. B. Chemicals & Pharmaceuticals Limited Fundamentals Summary
| JBCHEPHARM fundamental statistics | |
|---|---|
| Market cap | ₹281.50b |
| Earnings (TTM) | ₹7.18b |
| Revenue (TTM) | ₹40.92b |
Is JBCHEPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JBCHEPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹40.92b |
| Cost of Revenue | ₹13.69b |
| Gross Profit | ₹27.23b |
| Other Expenses | ₹20.05b |
| Earnings | ₹7.18b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 45.86 |
| Gross Margin | 66.55% |
| Net Profit Margin | 17.56% |
| Debt/Equity Ratio | 0.2% |
How did JBCHEPHARM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 11:18 |
| End of Day Share Price | 2025/12/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
J. B. Chemicals & Pharmaceuticals Limited is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| null null | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |